News | December 10, 2025
Lilly to invest $6 billion in Huntsville manufacturing hub
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Expands bioprocessing footprint across Asia
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
The study met its primary endpoint and all 11 secondary efficacy endpoints
While Merck can appeal, Halozyme said it expects the order to hold
Subscribe To Our Newsletter & Stay Updated
